Burooyinka qaangaarka ah ee T-cell, sida non-Hodgkin T-cell lymphoma, waa kuwo aad u kacsan oo u adkaysta daroogada, bukaanada badiyaa waxay leeyihiin saadaal xumo. Dhawaan, taxanaha "Dabeecadda" ee laba maqaal ayaa lagu daabacay fasiraad cusub oo ku saabsan cudurada faafa ee non-Hodgkin's T-cell lymphoma, sidaas darteedna u siinaya jihada cusub ee horumarinta wax ku oolka ah ee daaweynta cusub ee noocan ah lymphoma malignant.
Daraasaddii ugu horreysay, kooxda Wartewig waxay adeegsadeen borotiinka isku-dhafka ah ee ITK-SYK si ay u dhisaan qaabka jiirka transgenic ee lymphoma T-cell-ka dambe (Nature. Doi: 10.1038 / nature24649), waxayna ogaadeen in hal ama nuqul laba jeer ah PDCD1 hidda-sidaha codeeya borotiinka PD1 waa la tirtiray. Unugyada T-da ee lymphoma waxay ku dhacaan isbeddel xun oo degdeg ah waxayna dedejisaa dhimashada qaabka jiirka. Intaa waxaa dheer, codsiga PD1 ama PD-L1 inhibitors waxay soo saari karaan saameyn isku mid ah. Habka la xidhiidha ayaa ah in PD1 ay kor u qaaddo muujinta PTEN oo ay joojiso dariiqa faafinta buro malignant PI3K.
Maqaal kale, Maciocia et al. Daawaynta daawaynta unugyada difaaca jirka ee loo yaqaan 'chimeric antigen receptor T' (CAR-T) (Nat Med Doi: 10.1038 / nm.4444) si loo dhiso unugyada CAR-T ee si gaar ah u bartilmaameedsada TRBC1 laakiin aan ahayn TRBC2 Si loo daweeyo TRBC1-positive T-cell cancer. Iyadoo la dilayo unugyada burooyinka, ka tagaya unugyo T ku filan si ay ula dagaallamaan caabuqa. Tijaabada caafimaad ee habkan ayaa si rasmi ah loo bilaabi doonaa 2018.
Tifatiraha sare ee Dabeecadda Megan Cully ayaa sheegtay in natiijooyinka muhiimka ah ee aan kor kusoo xusnay ay bixinayaan istiraatiijiyad daaweyn cusub oo loogu talagalay daaweynta cudurada qaangaarka ee T-cellka waxayna ka digayaan in burooyinkaasi aysan ku habooneyn daaweynta PD1 ama PDL1 inhibitors.
